-
The authors randomized women with objectively validated heavy menstrual bleeding (mean menstrual blood loss [MBL] of 80 mL or more per cycle, confirmed using the alkaline hematin methodology during two pretreatment cycles) to treatment with oral tranexamic acid 3.9 g/d or placebo for up to 5 days per cycle for 6 menstrual cycles.
-
The rate of sepsis with group b streptococcus (gbs) in neonates of colonized mothers is now less than 1%.
-
-
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
The authors enrolled women desiring postpartum use of a levonorgestrel-releasing intrauterine system in a randomized trial to determine whether use of the device would be higher when insertion occurred immediately postpartum rather than delaying placement to the standard postpartum visit.
-
-
Nearly every reference source discussing the primary management of advanced ovarian cancer will highlight the role of surgical cytoreduction as an important first step in the care of this disease.
-
-
If you think your facility's efforts to stem the spread of HIV is working, you might need to redouble your efforts. Results of a new analysis of 21 major U.S. cities from the Centers for Disease Control and Prevention (CDC) indicate approximately one in five (19%) men who have sex with men (MSM) in a study is infected with HIV, and nearly half (44%) of those men are unaware of their infection.
-
While increased use of contraception has contributed to declines in teen pregnancy over the past two decades, the methods most teens choose oral contraceptive pills or condoms require ongoing maintenance and carry a high possibility of user errors.